Lupin Pharmaceuticals, a subsidiary of Lupin, has launched its Duloxetine 40 mg Delayed-Release (DR) Capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength. Lupin is excited to bring this new strength to market, as it adds to the currently-available dosing options for greater flexibility of treatment.
Lupin is the only generic manufacturer to offer all Duloxetine dosage strengths - the 20 mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin’s generic Duloxetine 40 mg DR capsules are therefore the first and only capsule available for patients in this dosage strength. Cymbalta Delayed-Release Capsules 20 mg, 30 mg and 60 mg strengths had annual U.S sales of approximately USD 1.05 billion (Brand + Generics - IMS MAT June 2015).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1515.00 |
Dr. Reddys Lab | 6080.25 |
Cipla | 1565.50 |
Zydus Lifesciences | 1110.95 |
Lupin | 1601.00 |
View more.. |